People with scleromyositis have symptoms of both systemic scleroderma and either polymyositis or dermatomyositis, and is therefore considered an overlap syndrome.
[2] Treatment of these patients is therefore strongly dependent on the exact symptoms with which a patient reports to a physician and is similar to treatment for the individual autoimmune disease, often involving either immunosuppressive or immunomodulating drugs.
The signs to look for include Raynaud's phenomenon, arthritis, myositis and scleroderma.
Blood studies and numerous other specialized tests depending upon which organs are affected.
[4] One study from 2014 showed some potential of the synthetic drug Rituximab in treating this class of overlap syndromes.